drugset / Trial / NCT03478605
Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
RandomizedParallel-groupOpen-labelTreatment
Summary
Olanzapine-containing regimens for CINV prophylaxis may provide even better protection than aprepitant-containing regimens.
Timeline
- Start
- 2018-05-25
- Primary completion
- 2019-05-25
- Completion
- 2019-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Olanzapine | Small molecule | 5 mg | Oral |
| Background | Dexamethasone | Small molecule | 8 mg | Intravenous |
| Background | Ondansetron | Other / unclassified | 16 mg | Intravenous |